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Abstract
Inflammation influences iron balance in the whole organism. A
common clinical manifestation of these changes is anemia of
chronic disease (ACD; also called anemia of inflammation). In-
flammation reduces duodenal iron absorption and increases mac-
rophage iron retention, resulting in low serum iron concentrations
(hyposideremia). Despite the protection hyposideremia provides
against proliferating microorganisms, this “iron withholding” re-
duces the iron available to maturing red blood cells and eventually
contributes to the development of anemia. Hepcidin antimicrobial
peptide (Hamp) is a hepatic defensin-like peptide hormone that
inhibits duodenal iron absorption and macrophage iron release.
Hamp is part of the type II acute phase response and is thought to
have a crucial regulatory role in sequestering iron in the context of
ACD. Mice with deficiencies in the hemochromatosis gene prod-
uct, Hfe, mounted a general inflammatory response after injection
of lipopolysaccharide but lacked appropriate Hamp expression
and did not develop hyposideremia. These data suggest a previ-
ously unidentified role for Hfe in innate immunity and ACD.
Comments
Hepcidin (also called Hamp) is an antimicrobial pep-
tide hormone synthesized by the liver,1 that has been lik-
ened to the defensins, small neutrophil-derived peptides
with roles in innate and adaptive immunity. There is ev-
idence from both human and mouse models that hepci-
din downregulates gastrointestinal iron absorption and
serum iron by inhibiting both intestinal iron absorption
and iron release from reticuloendothelial macrophage
storage sites.2 This inhibition can lead to abnormally low
serum iron concentrations (hypoferremia or hyposider-
emia).
Low serum iron in the face of high body iron stores is a
characteristic diagnostic feature of anemias of chronic dis-
ease (ACD),3,4 prompting suggestions that hepcidin is
important in the pathogenesis of ACD.5,6 These anemias,
also called anemias of inflammation, comprise a spectrum
of anemias associated with chronic diseases such as malig-
nancy, arthritis, infections and other inflammatory disor-
ders.3,4,7
The evidence that hepcidin modulates iron status in
both iron deficiency and iron overload has been recently
reviewed.8,9 Briefly, the hepatic expression of mouse hep-
cidin messenger RNA (mRNA) responds to iron status,
being increased during iron overload and decreased dur-
ing iron deficiency.10,11 Overexpression of hepcidin in
mice leads to severe iron deficiency anemia12 and inhibits
liver iron accumulation in the Hfe-knockout mouse
model of hemochromatosis.13 On the other hand, up-
stream stimulatory factor 2 (USF2) knockout mice, in
which endogenous hepcidin expression is disrupted, have
severe tissue iron overload which resembles that in Hfe-
knockout mice.2 In both these mouse models, this over-
load is thought to be due to increased intestinal
absorption of iron in conjunction with impaired reten-
tion in reticuloendothelial macrophages. In humans, mu-
tations in the hepcidin gene that disrupt the function of
hepcidin can result in juvenile hemochromatosis.14 Con-
versely, excessive expression of hepcidin from large he-
patic adenomas is associated with severe iron refractory
anemia5 These studies along with others support the con-
tention that hepcidin downregulates serum iron both by
reducing uptake of dietary iron and by inhibiting release
from body iron stores.
One protein involved in regulating hepcidin expres-
sion is HFE. Bridle et al.15 observed decreased hepatic
hepcidin mRNA levels in both Hfe-knockout mice and in
untreated patients with HFE-related hemochromatosis.15
Similar results have been reported by various other stud-
ies.16-19 Notably microarray analyses of hepatic gene ex-
pression also suggest hepcidin mRNA expression is
specifically decreased in mouse models of HFE-related
hemochromatosis whereas, in contrast, hepcidin expres-
sion is appropriately increased in mice with secondary
iron overload from iron-dextran injection.7,18
These findings raised the possibility that HFE might be
required for upregulation of hepcidin and consequent hy-
poferremia in response to inflammation. Roy et al.7 inves-
tigated this question by examining expression of hepcidin,
interleukin 6 (IL-6) and tumor necrosis factor (TNF) in
wild-type and Hfe-knockout mice 1.5 hours after lipo-
polysaccharide (LPS) treatment. At this time point, IL-6
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and TNF expression were elevated in both wild-type and
Hfe-knockout mice. However, despite the normal cyto-
kine response in Hfe-knockout mice in response to LPS-
induced inflammation, increases in hepatic hepcidin
mRNA levels and hypoferremia were not observed in this
study.7 These observations lead to the conclusion that the
lack of hepcidin up-regulation in Hfe-knockout mice was
“not due to an insufficient acute phase response” and
HFE must “act downstream, or independently of, IL-6 in
the inflammatory cascade” that upregulates hepcidin ex-
pression.7 Roy and colleagues therefore suggested that
preventing hypoferremia through “inhibition of HFE
function may be a new therapeutic approach to treating
ACD”.7
In contrast, two subsequent studies19,20 using compa-
rable mouse models have reported that hepcidin upregu-
lation during inflammation does not require Hfe. Frazer
et al.19 found that 16 hours after inducing an acute phase
inflammatory response by injecting Freund’s Complete
Adjuvant, hepatic hepcidin mRNA expression was signif-
icantly increased in Hfe-knockout mice and to an extent
similar to increases seen in wild-type mice. Hypoferremia
(indicated by decreased transferrin saturation) occurred in
both types of mice. Similarly Lee at al.20 demonstrated
that LPS treatment induced hepcidin expression in both
Hfe-knockout and wild-type mice and that IL-6 caused
equivalent upregulation of hepcidin mRNA levels in iso-
lated hepatocytes from both types of mice.
The results of these two studies19,20 argue that HFE is
not necessary for either hepcidin induction or hypoferre-
mia in response to inflammation. Frazer et al.19 propose
that hepatic hepcidin expression is usually regulated by an
HFE-dependent mechanism that can be stimulated di-
rectly or indirectly in response to iron in the intact animal.
However, during acute phase inflammatory response, this
mechanism can be overridden, allowing hepcidin to be
upregulated independent of HFE, possibly by a pathway
involving Toll-like receptor 4.19
The reasons for the disparities between Roy et al.7 and
the other two studies19,20 are not clear. One possibility is
that there may be short-term actions of the HFE-depen-
dent pathway on inflammation induced expression of
hepcidin that were detectable at the time used by Roy et
al.7 (1.5 hours after LPS injection; cytokine and hepcidin
responses returned to baseline by 24 hours) that might
have been missed by the other studies (6 hours20 or 16
hours19 after inflammatory stimuli). However, while
short-term actions may be important in other contexts,
long-term actions are more relevant to ACD, which is
typically associated with chronic disease and inflamma-
tion.
It remains unknown how modulating the levels of
HFE or hepcidin will affect inflammatory responses and
iron status over longer periods when superimposed on a
coexisting, chronic, inflammatory disease or infection. It
will be important to examine these questions in models
more closely representing human anemias of infection
and chronic disease.
ELIZABETH A. MILWARD, PH.D.1
DEBORAH TRINDER, PH.D.2
CHANTELLE E.J. WILCOX1
ROBERT S. BRITTON, PH.D.3
GRANT A. RAMM, PH.D.4
JOHN K. OLYNYK, M.D.2








3 Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St. Louis, MO
4 The Hepatic Fibrosis Group
The Queensland Institute of Medical Research
PO Royal Brisbane Hospital
Brisbane, QLD, Australia
References
1. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicro-
bial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810.
2. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A,
et al. Lack of hepcidin gene expression and severe tissue iron overload in
upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci
U S A 2001;98:8780-8785.
3. Means RT Jr. The anaemia of infection. Bailliere’s Best Practice Clin
Haematol 2000;13:151-162.
4. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood
Rev 2002;16:87-96.
5. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews
NC. Inappropriate expression of hepcidin is associated with iron refractory
anemia: implications for the anemia of chronic disease. Blood 2002;100:
3776-3781.
6. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The
gene encoding the iron regulatory peptide hepcidin is regulated by anemia,
hypoxia, and inflammation. J Clin Invest 2002;110:1037-1044.
7. Roy CN, Custodio AO, de Graaf J, Schneider S, Akpan I, Montross LK, et
al. An Hfe-dependent pathway mediates hyposideremia in response to
lipopolysaccharide-induced inflammation in mice. Nat Genet 2004;36:
481-485.
8. Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol 2004;11:251-
254.
9. Robson KJ. Hepcidin and its role in iron absorption. Gut 2004;53:617-
619.
10. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A
new mouse liver-specific gene, encoding a protein homologous to human
antimicrobial peptide hepcidin, is overexpressed during iron overload.
J Biol Chem 2001;276:7811-7819.
HEPATOLOGY, Vol. 41, No. 4, 2005 HEPATOLOGY ELSEWHERE 937
11. Mazur A, Feillet-Coudray C, Romier B, Bayle D, Gueux E, Ruivard M, et
al. Dietary iron regulates hepatic hepcidin 1 and 2 mRNAs in mice. Me-
tabolism 2003;52:1229-1231.
12. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp
B, et al. Severe iron deficiency anemia in transgenic mice expressing liver
hepcidin. Proc Natl Acad Sci U S A 2002;99:4596-4601.
13. Nicolas G, Viatte L, Lou DQ, Bennoun M, Beaumont C, Kahn A, et al.
Constitutive hepcidin expression prevents iron overload in a mouse model
of hemochromatosis. Nat Genet 2003;34:97-101.
14. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, et
al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile
hemochromatosis. Nat Genet 2003;33:21-22.
15. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH,
et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis
and the liver as a regulator of body iron homoeostasis. Lancet 2003;361:
669-673.
16. Ahmad KA, Ahmann JR, Migas MC, Waheed A, Britton RS, Bacon BR, et
al. Decreased liver hepcidin expression in the Hfe knockout mouse. Blood
Cells Mol Dis 2002;29:361-366.
18. Muckenthaler M, Roy CN, Custodio AO, Minana B, de Graaf J, Montross
LK, et al. Regulatory defects in liver and intestine implicate abnormal
hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat Genet
2003;34:102-107.
19. Frazer DM, Wilkins SJ, Millard KN, McKie AT, Vulpe CD, Anderson
GJ. Increased hepcidin expression and hypoferraemia associated with an
acute phase response are not affected by inactivation of HFE. Br J Haema-
tol 2004;126:434-436.
20. Lee P, Peng H, Gelbart T, Beutler E. The IL-6- and lipopolysaccharide-
induced transcription of hepcidin in HFE-, transferrin receptor 2-, and
beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci U S A
2004;101:9263-9265.
Copyright © 2005 by the American Association for the Study of Liver Diseases.
Published online in Wiley InterScience (www.interscience.wiley.com).
DOI 10.1002/hep.20652
Conflict of interest: Nothing to report.
938 HEPATOLOGY ELSEWHERE HEPATOLOGY, April 2005
